HC Wainwright Has Positive View of ALX Oncology Q3 Earnings

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for ALX Oncology to a loss of $0.13 per share from $0.14 previously, while projecting a $0.55 loss for full-year 2026.
• ALX Oncology reported a quarterly loss of $0.13 per share, beating analysts’ consensus estimate of a $0.14 loss by $0.01.
• The stock carries a “Moderate Buy” consensus rating from analysts, with five Buy ratings and one Sell rating and an average price target of $4.60; institutional investors own 97.97% of shares.

ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) - Analysts at HC Wainwright boosted their Q3 2026 earnings per share (EPS) estimates for shares of ALX Oncology in a research note issued to investors on Monday, August 10th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.13) for the quarter, up from their prior forecast of ($0.14). The consensus estimate for ALX Oncology's current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for ALX Oncology's Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.55) EPS, Q1 2027 earnings at ($0.13) EPS, Q4 2027 earnings at ($0.15) EPS, FY2027 earnings at ($0.57) EPS, FY2028 earnings at ($0.46) EPS, FY2029 earnings at ($0.51) EPS and FY2030 earnings at ($0.50) EPS.

ALX Oncology (NASDAQ:ALXO - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.01.

Several other equities research analysts also recently weighed in on ALXO. Weiss Ratings downgraded shares of ALX Oncology from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Wednesday, August 5th. Wall Street Zen raised shares of ALX Oncology from a "sell" rating to a "hold" rating in a research report on Saturday, May 9th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $4.60.

ALX Oncology Trading Down 1.0%

NASDAQ ALXO opened at $2.06 on Thursday. The firm has a 50 day simple moving average of $1.94 and a 200-day simple moving average of $1.97. The company has a debt-to-equity ratio of 0.07, a quick ratio of 9.71 and a current ratio of 9.71. ALX Oncology has a one year low of $0.80 and a one year high of $2.66. The firm has a market cap of $284.86 million, a price-to-earnings ratio of -1.82 and a beta of 0.42.

Institutional Trading of ALX Oncology

A number of large investors have recently made changes to their positions in the company. venBio Partners LLC acquired a new position in ALX Oncology during the 2nd quarter worth approximately $26,671,201,000. BlackRock Inc. acquired a new stake in shares of ALX Oncology in the 2nd quarter valued at $15,317,000. Redmile Group LLC raised its holdings in shares of ALX Oncology by 143.9% in the 1st quarter. Redmile Group LLC now owns 7,964,188 shares of the company's stock valued at $15,968,000 after purchasing an additional 4,699,470 shares in the last quarter. Vivo Capital LLC purchased a new stake in shares of ALX Oncology during the 1st quarter worth $6,385,000. Finally, 5AM Venture Management LLC purchased a new stake in shares of ALX Oncology during the 2nd quarter worth $6,328,663,000. 97.97% of the stock is currently owned by hedge funds and other institutional investors.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company's mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology's pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source